Royalty Pharma RPRX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total income and other revenues by Product | ||||||
| Income from financial royalty assets | $594.99M+10.3% | $592.43M+5.4% | $578.81M+8.6% | $550.42M+7.3% | $539.49M-0.4% | |
| Other royalty income and revenues | $35.58M+23.7% | $29.56M-7.0% | $30.48M-3.3% | $28.25M+15.8% | $28.76M+8.8% | |
| Total Commitments by Product | ||||||
| JNJ‑4804 | $500M— | —— | —— | —— | —— | |
| Litifilimab | $250M— | —— | —— | —— | —— | |
| Research and development commitment by Product | ||||||
| Phase 2b, TEV-408 | $75M— | —— | —— | —— | —— | |
| Phase 3, TEV-408 | $425M— | —— | —— | —— | —— | |
| Unfunded Commitments by Product | ||||||
| JNJ‑4804 | $500M— | —— | —— | —— | —— | |
| Litifilimab | $25M— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Royalty Pharma break its business down?
- Royalty Pharma (RPRX) reports total income and other revenues by product across 2 parts — Income from financial royalty assets and Other royalty income and revenues. Each is extracted from the segment footnotes and tracked over time.
- Where does Royalty Pharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Royalty Pharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
